Hyperoxaluria is common in calcium oxalate kidney stone formers and is typically associated with excessive intake of dietary oxalate or increased endogenous production. Oral oxalate-reducing enzymes break down dietary oxalate in the gastrointestinal tract resulting in reduced urinary oxalate. Objective: To explore an acid stable OxDC as a means to reduce urinary oxalate.
INTRODUCTION AND OBJECTIVES:
Hyperoxaluria is common in calcium oxalate kidney stone formers and is typically associated with excessive intake of dietary oxalate or increased endogenous production. Oral oxalate-reducing enzymes break down dietary oxalate in the gastrointestinal tract resulting in reduced urinary oxalate. Objective: To explore an acid stable OxDC as a means to reduce urinary oxalate.
METHODS: This was a prospective, double-blind, randomized, placebo-controlled, cross-over study that evaluated an orally administered OxDC in normal healthy volunteers with BMI of 18.5e29.9 kg/m2, and urinary oxalate (UOx) <40.5mg/24 hours. Subjects were randomized to 2 different cross-over sequences separated by a washout period of 2 days. A controlled diet (750-800 mg oxalate, 500-550 mg calcium per day) was utilized and six 24-hour UOx were measured. Subjects were given approximately 1000 units (ï mol/min/mg) of enzyme or representative placebo with meals 3 times per day over 4 treatment days.
RESULTS: Thirty-three healthy subjects (16 female, 17 male) with a mean age of 36.2 years (range 19-53 years) completed the study. The mean eGFR and BMI were 96.8 (SD 18) and 24.7 (SD 3.1), respectively. On controlled diet, and controlled diet with placebo, mean urinary oxalate was approximately 43mg/24h and 40mg/24h, respectively. On treatment, average urinary oxalate was significantly reduced to approximately 30mg/24h. Preliminary data analysis indicates that there were no significant differences in any of the other urinary parameters measured (Ca, Cr, Mg, Cit, Uric). Reduction was seen in 31/33 subjects (94%). Baseline corrected within-subject mean difference in 24h UOx between treatment groups was 12.6mg or 30% (p<0.0001). There were no serious adverse events (AEs). All AEs were mildmoderate. There were no treatment related AEs. No subjects discontinued study treatment.
CONCLUSIONS: Oxalate decarboxylase is an orally administered oxalate reducing enzyme capable of significantly reducing UOx levels without having an effect on creatinine clearance, urine creatinine or other solutes related to supersaturation of calcium oxalate.
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PD38-02 IDENTIFICATION OF ABERRANT GLYCOSYLATION OF OSTEOPONTIN IN URINARY STONE FORMER PATIENTS AS A UROLITHIASIS BIOMARKER
Go Anan*, Sendai, Japan; Tohru Yoneyama, Yuki Tobisawa, Shingo Hatakeyama, Mihoko Yoneyama, Hirosaki, Japan; Hiromichi Iwamura, Jun Ito, Yasuhiro Kaiho, Sendai, Japan; Hayato Yamamoto, Hirosaki, Japan; Atsushi Imai, Sendai, Japan; Takahiro Yoneyama, Yasuhiro Hashimoto, Hirosaki, Japan; Makoto Sato, Sendai, Japan; Chikara Ohyama, Hirosaki, Japan INTRODUCTION AND OBJECTIVES: Osteopontin (OPN) is one of the most important components in calcium stone matrix. However, the mechanism by which OPN glycosylation affects stone formation processes is unclear. The aim of this study, to compare the glycosylation profile of OPN between stone former and healthy volunteer.
METHODS: Between 2015 and 2018, glycan profile of OPN in urine were measured in 133 stone former patients and 157 healthy volunteers using a lectin immunoblotting analysis and lectin array. The OPN concentration in urine was measured by ELISA method. The protocol was approved by the institutional committee on ethics in human investigation.
RESULTS: To examined glycan profile of OPN, lectin immunoblotting and lectin array analysis showed that polylactosamine carrying O-glycosylated OPN (PolyLacNAc-OPN) in urine was significantly increased in stone former patients than that of healthy volunteers, whereas OPN concentration in urine was significantly decreased in stone former patients than that of healthy volunteers (p<0.001). We investigated whether urinary OPN concentration and PolyLacNAc-OPN can predict urinary calculi, and it was possible to detect stone former with sensitivity of 90% and specificity of 92% (AUC 0.953) from ROC analysis. Furthermore, we prospectively investigated that urinary PolyLacNAc-OPN in stone former patients has tended to decrease after urinary calculi treatment compared with before treatment, whereas OPN concentration in urine has tended to increase after urinary calculi treatment compared with before treatment.
CONCLUSIONS: PolyLacNAc-OPN was significantly increased in stone former patients, suggesting the possibility of becoming a biomarker of urolithiasis formation.
